Director
Liver Institute of Virginia, Bon Secours Mercy Health
Richmond, VA, United States
Mitchell L. Shiffman, MD, FACG, is the Director of the Liver Institute of Virginia, with offices in Richmond and Newport News, VA. He received his MD degree from the State University of New York, Upstate Medical Center in Syracuse, NY. He completed internship and residency training in Internal Medicine and fellowship training in Gastroenterology and Hepatology at the Virginia Commonwealth University Medical Center. He served as the Chief of the Hepatology Section and Medical Director of the Liver Transplant Program at the Virginia Commonwealth University Medical Center in Richmond, VA, from 1990-2009. Dr. Shiffman joined the Bon Secours Health System and started the Liver Institute of Virginia in 2010. Dr. Shiffman is considered an International Key Opinion Leader in Hepatology, is a consultant to many pharmaceutical companies working in this space, and a site principle investigator for numerous clinical trials involving various liver diseases. Dr. Shiffman has published over 350 original articles, reviews, and/or book chapters, has edited 3 textbooks on liver disease, and was the Guest Editor for the Fall 2021 issue of Clinics in Liver Disease on Chronic hepatitis B Virus. He served as a member of the ACG Board of Trustees from 2003-2009 and was a member of the ACG Institute Board between 2005-2013. He is currently an Associate Editor of the ACG Education Universe. Dr. Shiffman has served on numerous ACG committees and NIH grant review committees and is a regular reviewer for several medical journals.
AbbVie (Individual(s) Involved: Self): Advisory Committee/Board Member, Speaker's Bureau; Celgene (Individual(s) Involved: Self): Grant/Research Support; Cyma Bay (Individual(s) Involved: Self): Grant/Research Support; Durect (Individual(s) Involved: Self): Grant/Research Support; Eisai (Individual(s) Involved: Self): Advisory Committee/Board Member, Speaker's Bureau; Enanta (Individual(s) Involved: Self): Grant/Research Support; Galectin (Individual(s) Involved: Self): Grant/Research Support; Genentech (Individual(s) Involved: Self): Speaker's Bureau; Genfit (Individual(s) Involved: Self): Grant/Research Support; Gilead (Individual(s) Involved: Self): Advisory Committee/Board Member, Grant/Research Support, Speaker's Bureau; Hanmi (Individual(s) Involved: Self): Grant/Research Support; HepQuant (Individual(s) Involved: Self): Advisory Committee/Board Member, Grant/Research Support; HighTide (Individual(s) Involved: Self): Grant/Research Support; Intercept (Individual(s) Involved: Self): Advisory Committee/Board Member, Grant/Research Support, Speaker's Bureau; Mirum (Individual(s) Involved: Self): Grant/Research Support; Novo Nordisk (Individual(s) Involved: Self): Grant/Research Support; Pliant (Individual(s) Involved: Self): Grant/Research Support; Viking Therapeutics (Individual(s) Involved: Self): Grant/Research Support